A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma

Phase 1

• Conditions: Advanced Sarcoma; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: EUCTR2019-004310-33-ES
• Lead Sponsor: Dr. Antonio Pérez Martínez

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-06-22
• Last Update Posted: 2 March 2022

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

•Age: < 30 years at the time of recurrence or progression with any type of sarcoma that has recurred or not responded to standard therapy and is deemed incurable by standard therapy.
•Positive NKG2DL expression in sarcoma samples. Ideally, they should have centralized histological verification of NKG2DL expression in sarcoma samples (positive expression is defined as at least 2+ expression (0-4+ scale) in >50 percent of the tumor cells using anti-MICA and or anti-ULBP2). Patients will undergo biopsy following enrollment to obtain tissue to assess NKG2DL expression, with the following restrictions:
oIf the patient doesn´t have adequate accessible tumor for biopsy (at least 1 cm diameter).
oProcedures employed to acquire biopsies for tumor lysates will be limited to percutaneous needle or core biopsies, thoracoscopic excision or open biopsies of readily accessible lesions. Pulmonary lesions may be biopsied but extensive surgery such as thoracotomy or laparotomy should not be employed.
oPatients who require biopsy should not be enrolled if in the opinion of the principal investigator (PI), the tumor site places the patient at substantial related risk from the biopsy procedure.
In patients that fulfill any of these restrictions, when adequate archived tissue is available, this may be utilized to assess NKG2DL expression.
•Patient must have either measurable or evaluable tumor.
•The tumor must be accessible for intralesional administration of CAR T cells (only in ARM B).
•Life expectancy of at least 10 weeks in opinion of the principal investigator (PI).
•Lansky (age<16 years) or Karnofsky (age >=16 years) score of 50 or greater.
•Patients must have recovered from the acute toxic effects of all prior anticancer therapy (including chemotherapy and radiotherapy).
•Adequate bone marrow function defined by an absolute neutrophil count (ANC) of >/= 1.000/µL, platelet count of >/= 30.000/µL and hemoglobin of >/= 9.0 g/dl, and absence of a regular red blood cell and platelet transfusion requirement.
•Patients should have a normal hepatic function with a total bilirubin <2 times the upper limit of normal and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) < 2 times the upper limit of normal, and adequate renal function as defined by a serum creatinine = 1.5 upper limit of normal.
•Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent
•Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the infusion. Male partner should use a condom.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for at least 6 months after the NKG2D-CAR T infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests. Highly effective contraception methods include:
oTotal abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (eg: calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
oUse of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that hav

Exclusion Criteria

•Enrolled in another treatment protocol
•Evidence of untreated and active infection or clinically significant systemic illness:
oCardiac disorder defined as LVFE < 45% determined by ECHO.
oHuman Immunodeficiency Virus (HIV) positive test.
oPresence of active or prior CMV, EBV, hepatitis B or C as indicated by serology.
oAny significant pulmonary, hepatic or other organ dysfunction
•Chronic corticosteroid dependence (except replacement therapy)
•Evidence of any toxicity grade = 4 (according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.3)
•Pregnant or lactating women.
•Medical history of epilepsy.
•Any other condition that, in the opinion if the PI, may interfere with the efficacy and/or safety evaluation of the trial.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified